Literature DB >> 17035317

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Theodore Oliphant1, Grant E Nybakken, Michael Engle, Qing Xu, Christopher A Nelson, Soila Sukupolvi-Petty, Anantha Marri, Bat-El Lachmi, Udy Olshevsky, Daved H Fremont, Theodore C Pierson, Michael S Diamond.   

Abstract

Previous studies have demonstrated that monoclonal antibodies (MAbs) against an epitope on the lateral surface of domain III (DIII) of the West Nile virus (WNV) envelope (E) strongly protect against infection in animals. Herein, we observed significantly less efficient neutralization by 89 MAbs that recognized domain I (DI) or II (DII) of WNV E protein. Moreover, in cells expressing Fc gamma receptors, many of the DI- and DII-specific MAbs enhanced infection over a broad range of concentrations. Using yeast surface display of E protein variants, we identified 25 E protein residues to be critical for recognition by DI- or DII-specific neutralizing MAbs. These residues cluster into six novel and one previously characterized epitope located on the lateral ridge of DI, the linker region between DI and DIII, the hinge interface between DI and DII, and the lateral ridge, central interface, dimer interface, and fusion loop of DII. Approximately 45% of DI-DII-specific MAbs showed reduced binding with mutations in the highly conserved fusion loop in DII: 85% of these (34 of 40) cross-reacted with the distantly related dengue virus (DENV). In contrast, MAbs that bound the other neutralizing epitopes in DI and DII showed no apparent cross-reactivity with DENV E protein. Surprisingly, several of the neutralizing epitopes were located in solvent-inaccessible positions in the context of the available pseudoatomic model of WNV. Nonetheless, DI and DII MAbs protect against WNV infection in mice, albeit with lower efficiency than DIII-specific neutralizing MAbs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035317      PMCID: PMC1676294          DOI: 10.1128/JVI.01732-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.

Authors:  Carl W Davis; Hai-Yen Nguyen; Sheri L Hanna; Melissa D Sánchez; Robert W Doms; Theodore C Pierson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Neutralizing monoclonal antibodies against Russian strain of the West Nile virus.

Authors:  Ivan A Razumov; Elena I Kazachinskaia; Vladimir A Ternovoi; Elena V Protopopova; Irina V Galkina; Valentin L Gromashevskii; Alexander G Prilipov; Alla V Kachko; Alla V Ivanova; Dimitry K L'vov; Valery B Loktev
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

3.  Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.

Authors:  L Hannah Gould; Jianhua Sui; Harald Foellmer; Theodore Oliphant; Tian Wang; Michel Ledizet; Akikazu Murakami; Kristin Noonan; Cassandra Lambeth; Kalipada Kar; John F Anderson; Aravinda M de Silva; Michael S Diamond; Raymond A Koski; Wayne A Marasco; Erol Fikrig
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Crystal structure of the West Nile virus envelope glycoprotein.

Authors:  Grant E Nybakken; Christopher A Nelson; Beverly R Chen; Michael S Diamond; Daved H Fremont
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

5.  Complement activation is required for induction of a protective antibody response against West Nile virus infection.

Authors:  Erin Mehlhop; Kevin Whitby; Theodore Oliphant; Anantha Marri; Michael Engle; Michael S Diamond
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages.

Authors:  J S Peiris; S Gordon; J C Unkeless; J S Porterfield
Journal:  Nature       Date:  1981-01-15       Impact factor: 49.962

7.  Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.

Authors:  M W Brandriss; J J Schlesinger; E E Walsh; M Briselli
Journal:  J Gen Virol       Date:  1986-02       Impact factor: 3.891

8.  Characterization of neutralizing antibodies to West Nile virus.

Authors:  Melissa D Sánchez; Theodore C Pierson; Douglas McAllister; Sheri L Hanna; Bridget A Puffer; Laura E Valentine; Mariam M Murtadha; James A Hoxie; Robert W Doms
Journal:  Virology       Date:  2005-05-25       Impact factor: 3.616

9.  Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.

Authors:  Theodore Oliphant; Michael Engle; Grant E Nybakken; Chris Doane; Syd Johnson; Ling Huang; Sergey Gorlatov; Erin Mehlhop; Anantha Marri; Kyung Min Chung; Gregory D Ebel; Laura D Kramer; Daved H Fremont; Michael S Diamond
Journal:  Nat Med       Date:  2005-04-24       Impact factor: 53.440

10.  Structural basis of West Nile virus neutralization by a therapeutic antibody.

Authors:  Grant E Nybakken; Theodore Oliphant; Syd Johnson; Stephen Burke; Michael S Diamond; Daved H Fremont
Journal:  Nature       Date:  2005-09-29       Impact factor: 49.962

View more
  185 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

2.  B-cell responses during primary and secondary dengue virus infections in humans.

Authors:  Anuja Mathew; Kim West; Siripen Kalayanarooj; Robert V Gibbons; Anon Srikiatkhachorn; Sharone Green; Daniel Libraty; Smita Jaiswal; Alan L Rothman
Journal:  J Infect Dis       Date:  2011-09-19       Impact factor: 5.226

3.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

4.  Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Authors:  Roudaina Nasser; Mireia Pelegrin; Henri-Alexandre Michaud; Marc Plays; Marc Piechaczyk; Laurent Gros
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

5.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

6.  Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity.

Authors:  Poornima Parameswaran; Patrick Charlebois; Yolanda Tellez; Andrea Nunez; Elizabeth M Ryan; Christine M Malboeuf; Joshua Z Levin; Niall J Lennon; Angel Balmaseda; Eva Harris; Matthew R Henn
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

7.  Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis.

Authors:  Ruchi Srivastava; Chandran Ramakrishna; Edouard Cantin
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

8.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

9.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype.

Authors:  Petr Danecek; Wenzhe Lu; Catherine H Schein
Journal:  J Mol Biol       Date:  2009-12-04       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.